Protara Therapeutics Q3 EPS $(0.87) Beats $(0.98) Estimate; Cash, Cash Equivalents And Investments Of $74M As Of September 30, 2023 Expected To Fund Operations Into Q2 Of 2025
Portfolio Pulse from Benzinga Newsdesk
Protara Therapeutics reported Q3 losses of $(0.87) per share, beating the analyst consensus estimate of $(0.98) by 11.22 percent. This is a 27.94 percent decrease over losses from the same period last year. The company has cash, cash equivalents and investments of $74M as of September 30, 2023, which is expected to fund operations into Q2 of 2025.
November 03, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Protara Therapeutics reported better than expected Q3 earnings and has sufficient cash to fund operations into Q2 2025.
Protara Therapeutics reported a smaller loss than expected, which is generally seen as positive by the market. Additionally, the company's cash position is strong, which reduces financial risk and provides funding for future operations. This is likely to have a positive impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100